Key result
Combining echocardiography, ECG, and blood biomarkers improves screening accuracy for amyloid cardiomyopathy.
Why the study?
Echocardiography is important for screening cardiac amyloidosis, but typical findings like granular sparkling and apical sparing have limitations and require comprehensive assessment.
Echocardiography is a crucial screening tool for cardiac amyloidosis, especially when combining findings like apical sparing and wall thickness-ECG voltage discrepancy with comprehensive clinical assessment.
Echocardiographic hypertrophy–ECG voltage mismatch or apical sparing may prompt amyloid workup; leaves open standardized criteria versus HCM or storage disease mimics.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Usuku et al. (2023) conducted a review in Amyloid cardiomyopathy. Echocardiography was evaluated. Echocardiography is essential for diagnosing amyloid cardiomyopathy, but comprehensive evaluation combining echocardiographic, electrocardiographic, and blood test findings is required for accurate screening.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: